Celgene GmbH
Industry / private company
Location:
München,
Germany (DE)
ISNI: 0000 0004 0377 4220
Insights From the Apremilast After Switching From Fumaric Acid Ester Treatment (APART) Study: An Interim Real-World Safety Analysis (2020)
Mrowietz U, Ertner K, Sticherling M, Grosse V, Popp G, Schwichtenberg U, Karl L, et al.
Conference contribution
First real-world insights on benefit of apremilast treatment in patients with moderate to severe psoriasis after switching from fumaric acid esters from the APART Study - an interim analysis (2019)
Mrowietz U, Ertner K, Sticherling M, Grosse V, Popp G, Roemmler-Zehrer J, Lampl M, et al.
Conference contribution